6120 RESULTS
Sort By:
CONFERENCE COVERAGE 2023-11-18 Conference Coverage As researchers parse what makes amyloid immunotherapy work, one answer keeps bubbling up: Take out all plaque quickly, so that clinical benefits have time to show up. At last month’s Clinical Trials on Alzheimer’s Disease conference, h
CONFERENCE COVERAGE 2023-11-17 Conference Coverage Can γ-secretase modulators stage a comeback? Scientists led by Irene Gerlach at F. Hoffmann-La Roche, Basel, Switzerland, are banking on it. At this year’s CTAD meeting, held October 24-27 in Boston, they reported that RG6289, a second
RESEARCH NEWS 2023-11-17 Research News Neuritic plaques, tau phosphorylation, microgliosis—of all the ways Aβ42 could doom the brain, few scientists might have suspected that it cripples γ-secretase, the very enzyme that creates it. Yet that is just what monomers do, according to
RESEARCH NEWS 2023-11-17 Research News A massive collaborative effort has shed some light on the mechanisms at work in progressive supranuclear palsy, a neurodegenerative tauopathy that ravages movement, balance, and cognition. In a manuscript posted November 13 on bioRxiv, resea
CONFERENCE COVERAGE 2023-11-11 Conference Coverage Current amyloid immunotherapies poorly enter the brain, with only one in a thousand antibodies getting through. For several years, researchers have been exploring alternate delivery methods that could allow for lower dosing and higher
CONFERENCE COVERAGE 2023-11-10 Conference Coverage While the trials, tribulations, and successes of Aβ immunotherapy were commanding Alzheimerologists' rapt attention, a different anti-amyloid approach has been quietly moving forward on the sidelines. PRI-002—a small molecule that
CONFERENCE COVERAGE 2023-11-09 Conference Coverage As the proteopathic drivers of Alzheimer's disease, Aβ and tau have for decades kept scientists trying to understand which of their isoforms and fragments are most to blame for the memory-robbing pathogenic cascade—and which ones
CONFERENCE COVERAGE 2023-11-08 Conference Coverage Some researchers have long argued for starting amyloid immunotherapy early, before tangles spread and neurons die all over the brain. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 24 to 27 in Boston and on
CONFERENCE COVERAGE 2023-11-05 Conference Coverage Evidence suggests that ethnoracial groups in the U.S. have different rates of age-related dementias, with Hispanic/Latino and black or African American people generally being more affected and Asian-Americans being less affected than w
CONFERENCE COVERAGE 2023-11-05 Conference Coverage Despite evidence that African American, Hispanic and Latino, and other minority groups have higher rates of Alzheimer’s and related dementias in the U.S., these populations are less likely to take part in clinical studies. This underre
RESEARCH NEWS 2023-11-04 Research News In their growing interest in the brain's border tissues, Alzheimerologists realize that they know little about some of its cells. One new study now sheds light on the astrocytes that form the glia limitans, which separates the brain
RESEARCH NEWS 2023-11-03 Research News Bright spots called white-matter hyperintensities (WMHs) often appear on MRI scans of people with familial or sporadic Alzheimer’s disease, and they tend to intensify as the disease progresses. Some scientists think they reflect cerebrovascu
RESEARCH NEWS 2023-11-03 Research News Because certain variants in TREM2 increase a person's risk of developing Alzheimer’s disease, how this microglial receptor influences AD pathology is an area of intense investigation. Now, researchers led by Zhentao Zhang, Renmin Hospit
CONFERENCE COVERAGE 2023-10-27 Conference Coverage Inflammation can be a helpful response to the common cold or the bite of an insect, but dangerous if it persists. In neurodegeneration, chronic micro- and astrogliosis spell trouble for the brain. Does it have to be that way? Over the
RESEARCH NEWS 2023-10-26 Research News Though APOE4 is the strongest genetic risk factor for sporadic Alzheimer’s disease, scientists have struggled for decades to figure out how it affects the cells of the brain. For microglia, at least, there may be some clarity. In the Septem
